Literature DB >> 14737978

[HLA-G: immunoregulatory molecule involved in allograft acceptance].

C Creput1, A Durrbach, B Charpentier, E D Carosella, N Rouas-Freiss.   

Abstract

The Human Leucocyte Antigen-G (HLA-G) is a non-classical MHC class I molecule of low polymorphism, restricted tissue distribution and tolerogeneic functions. It is clearly demonstrated that HLA-G contributes to fetal graft tolerance by the maternal immune system. The tolerogeneic properties of HLA-G act via specific inhibitory receptors present on immunocompetents cells: HLA-G inhibits natural killer cells (NK) and CD8+ T cell cytotoxicity, suppresses CD4+ T cell proliferation in response to allogeneic stimulation and promotes T helper 2 (Th2) type responses. The soluble HLA-G protein is spontaneously secreted by allo-sensitized CD4+ T cells during mixed lymphocyte reactions (MLR), and inhibits their proliferative response. Finally, inhibition of dendritic cell maturation has been observed in HLA-G transgenic mice. In human organ transplantation, our group has reported in cardiac and liver-kidney transplanted patients, a positive correlation between the de novo ectopic expression of HLA-G in both patient's serum and graft biopsies, and a lower rate of acute rejection episodes of the grafts. Moreover no chronic graft rejection has been detected in those populations. These results support the involvement of HLA-G in regulatory mechanisms that may occur during human allotransplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14737978

Source DB:  PubMed          Journal:  Nephrologie        ISSN: 0250-4960


  7 in total

1.  Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.

Authors:  Frédéric Gros; Yasmine Sebti; Sophie de Guibert; Bernard Branger; Marc Bernard; Renée Fauchet; Laurence Amiot
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

2.  The plasma levels of soluble HLA-G molecules correlate directly with CD34+ cell concentration and HLA-G 14bp insertion/insertion polymorphism in cord blood donors.

Authors:  Cristina Capittini; Paola Bergamaschi; Sara Sachetto; Mariarosa Truglio; Monica Viola; Andrea Marchesi; Valeria Genovese; Bina Romano; Marco Guarene; Rossella Poma; Miryam Martinetti; Carmine Tinelli; Laura Salvaneschi
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

3.  Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding.

Authors:  Roberta Rizzo; Alessandro Trentini; Daria Bortolotti; Maria C Manfrinato; Antonella Rotola; Massimiliano Castellazzi; Loredana Melchiorri; Dario Di Luca; Franco Dallocchio; Enrico Fainardi; Tiziana Bellini
Journal:  Mol Cell Biochem       Date:  2013-06-05       Impact factor: 3.396

4.  Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells.

Authors:  Aisha Nasef; Alain Chapel; Christelle Mazurier; Sandrine Bouchet; Manuel Lopez; Noelle Mathieu; Luc Sensebé; Yizhuo Zhang; Norbert-Claude Gorin; Dominique Thierry; Loïc Fouillard
Journal:  Gene Expr       Date:  2007

5.  Natural killer cells modulation in hematological malignancies.

Authors:  Céline Baier; Aurore Fino; Carole Sanchez; Laure Farnault; Pascal Rihet; Brigitte Kahn-Perlès; Régis T Costello
Journal:  Front Immunol       Date:  2013-12-19       Impact factor: 7.561

6.  Serum levels of soluble HLA-G correlate with disease activity in pediatric patients with Crohn's disease.

Authors:  Murat Cansever; Mehmet Akif Göktaş; Duran Arslan; Türkan Patiroğlu
Journal:  Saudi J Gastroenterol       Date:  2022 May-Jun       Impact factor: 3.214

7.  HLA-G UTR haplotype conservation in the Malian population: association with soluble HLA-G.

Authors:  Federico Carlini; Karim Traore; Nissem Cherouat; Pierre Roubertoux; Stéphane Buhler; Martì Cortey; Sophie Simon; Ogobara Doumbo; Jacques Chiaroni; Christophe Picard; Julie Di Cristofaro
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.